| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f41a868f49ca4f32d18d861e3afb411
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a5511d171c3e1eb82c61cf7e5ad1663 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-884
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3069
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001194 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate |
2017-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_808c610b633444dcb31094ee719e00df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35d9581b606d784942a5497548ed126b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b98ffc0a6a38f8481f97ea5e5e72ef2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d91a691a3c24d18f4bdc7c7bbfba33b1 |
| publicationDate |
2020-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3693396-A2 |
| titleOfInvention |
Psma binding antibody and uses thereof |
| abstract |
The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin. |
| priorityDate |
2016-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |